HUP0400458A2 - Kobalaminkötő fehérjéket expresszáló transzgenikus növények - Google Patents

Kobalaminkötő fehérjéket expresszáló transzgenikus növények

Info

Publication number
HUP0400458A2
HUP0400458A2 HU0400458A HUP0400458A HUP0400458A2 HU P0400458 A2 HUP0400458 A2 HU P0400458A2 HU 0400458 A HU0400458 A HU 0400458A HU P0400458 A HUP0400458 A HU P0400458A HU P0400458 A2 HUP0400458 A2 HU P0400458A2
Authority
HU
Hungary
Prior art keywords
transgenic plants
binding proteins
plants expressing
cobalamin binding
cobalamin
Prior art date
Application number
HU0400458A
Other languages
English (en)
Inventor
Lars Berglund
Torben Ellebaek Petersen
Sergey Nikolaevich Fedosov
Ebba Nexo
Niels Bech Laursen
Erik Ostergaard Jensen
Original Assignee
Cobento Biotech A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cobento Biotech A/S filed Critical Cobento Biotech A/S
Publication of HUP0400458A2 publication Critical patent/HUP0400458A2/hu
Publication of HUP0400458A3 publication Critical patent/HUP0400458A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
    • A01H1/00—Processes for modifying genotypes ; Plants characterised by associated natural traits
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Environmental Sciences (AREA)

Abstract

A találmány tárgyát általánosságban kobalamin megkötésére képesrekombináns fehérjék transzgenikus növényekkel történő termeltetéseképezi. A találmány szerinti rekombináns fehérjéket profilaktikusanés/vagy terápiásan kobalaminhiány kezelésére, valamint analitikaicélokra lehet alkalmazni. Ó
HU0400458A 2001-07-13 2002-07-12 Transgenic plants expressing cobalamin binding proteins HUP0400458A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0117171A GB2377446B (en) 2001-07-13 2001-07-13 Expression of cobalamin binding proteins in transgenic plants
PCT/GB2002/003227 WO2003006661A2 (en) 2001-07-13 2002-07-12 Transgenic plants expressing cobalamin binding proteins

Publications (2)

Publication Number Publication Date
HUP0400458A2 true HUP0400458A2 (hu) 2004-11-29
HUP0400458A3 HUP0400458A3 (en) 2005-06-28

Family

ID=9918480

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400458A HUP0400458A3 (en) 2001-07-13 2002-07-12 Transgenic plants expressing cobalamin binding proteins

Country Status (16)

Country Link
US (5) US20040268440A1 (hu)
EP (1) EP1417320A2 (hu)
JP (1) JP2004533851A (hu)
KR (1) KR20040027876A (hu)
CN (1) CN1549862A (hu)
BR (1) BR0211130A (hu)
CA (1) CA2453574A1 (hu)
EA (1) EA200400174A1 (hu)
GB (1) GB2377446B (hu)
HU (1) HUP0400458A3 (hu)
IL (1) IL159817A0 (hu)
MX (1) MXPA04000377A (hu)
NZ (1) NZ531026A (hu)
PL (1) PL367827A1 (hu)
WO (1) WO2003006661A2 (hu)
ZA (1) ZA200400751B (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1782063A2 (en) * 2004-07-29 2007-05-09 Cobento Biotech A/S Methods for determining proteins and protein-bound compounds comprising enzymatic modification
US7790363B2 (en) 2005-02-07 2010-09-07 Abbott Laboratories Inc. Diagnostic test for vitamin B12
WO2016041886A1 (en) * 2014-09-15 2016-03-24 Nestec S.A. Method for determining vitamin b12 uptake
US10716827B2 (en) 2015-05-20 2020-07-21 Syracuse University Compositions and methods for enhancing peptide stability against protease digestion
US20180154007A1 (en) * 2015-05-20 2018-06-07 Syracuse University Glycemic Control Using Intrinsic Factor Bound to A Vitamin B12 Conjugate of a Glucagon-Like Peptide-1 Receptor Agonist
EP3972432A4 (en) * 2019-05-20 2023-07-05 Syracuse University PHARMACEUTICAL FORMULATIONS AND METHODS FOR DELIVERING A THERAPEUTIC, DIAGNOSTIC OR CONTRAST AGENT TO CD206
WO2021030166A1 (en) * 2019-08-09 2021-02-18 Siemens Healthcare Diagnostics Inc. Anti-hog tcn1 monoclonal antibodies and methods of production and use thereof
WO2023089616A1 (en) * 2021-11-18 2023-05-25 Imagindairy Ltd. Food compositions comprising recombinant cells comprising transcobalamin

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3591678A (en) * 1969-09-05 1971-07-06 American Cyanamid Co Method of purifying intrinsic factor
US4279886A (en) * 1979-01-02 1981-07-21 University Patents, Inc. Test for pancreatic exocrine function
SU1751207A1 (ru) 1990-04-20 1992-07-30 Институт общей генетики им.Н.И.Вавилова Рекомбинантна плазмидна ДНК pST20, кодирующа альфа-интерферон человека в растени х табака
JPH0549478A (ja) * 1991-06-06 1993-03-02 Kanegafuchi Chem Ind Co Ltd ヒト内因子をコードするｄｎａ配列
US5548064A (en) * 1993-05-24 1996-08-20 Biotech Australia Pty Limited Vitamin B12 conjugates with EPO, analogues thereof and pharmaceutical compositions
US5939288A (en) * 1995-06-07 1999-08-17 Iowa State University Research Foundation, Inc. Plant secretory signal peptides and nectarins
US5959187A (en) * 1996-09-26 1999-09-28 Bailey; James E. Expression of oxygen-binding proteins in plants
WO2000037610A2 (en) * 1998-12-23 2000-06-29 Boyce Thompson Institute For Plant Research At Cornell Expression of immunogenic hepatitis b surface antigens in transgenic plants
DE60044858D1 (de) * 1999-10-26 2010-09-30 Stichting Dienst Landbouwkundi Säugetierartige Glykosylierung in Pflanzen
CN1301718A (zh) * 1999-12-27 2001-07-04 上海博德基因开发有限公司 一种新的多肽——钴胺素结合蛋白10和编码这种多肽的多核苷酸
WO2002064750A2 (en) * 2001-02-14 2002-08-22 Ventria Bioscience Expression system for seed proteins
CA2614998C (en) * 2005-07-12 2015-03-17 Greenovation Biotech Gmbh Production of sialylated glycoproteins in bryophytes

Also Published As

Publication number Publication date
PL367827A1 (en) 2005-03-07
EA200400174A1 (ru) 2005-06-30
MXPA04000377A (es) 2005-03-07
US20150157731A1 (en) 2015-06-11
US20150158920A1 (en) 2015-06-11
JP2004533851A (ja) 2004-11-11
US20040268440A1 (en) 2004-12-30
US20100184642A1 (en) 2010-07-22
CA2453574A1 (en) 2003-01-23
CN1549862A (zh) 2004-11-24
IL159817A0 (en) 2004-06-20
WO2003006661A3 (en) 2003-07-24
ZA200400751B (en) 2005-04-29
NZ531026A (en) 2005-09-30
WO2003006661A2 (en) 2003-01-23
GB2377446B (en) 2005-06-29
BR0211130A (pt) 2004-10-26
KR20040027876A (ko) 2004-04-01
EP1417320A2 (en) 2004-05-12
US9751918B2 (en) 2017-09-05
US20150158922A1 (en) 2015-06-11
GB0117171D0 (en) 2001-09-05
GB2377446A (en) 2003-01-15
HUP0400458A3 (en) 2005-06-28

Similar Documents

Publication Publication Date Title
HUP0402162A2 (hu) A humán angiopoietin-2 specifikus kötőanyagai
PL1615952T3 (pl) Sposoby leczenia chorób zapalnych z zastosowaniem środków specyficznie wiążących ludzką angiopoetynę-2
EP1404851A4 (en) PRODUCTION OF PLANT PROTEINS
MXPA04003487A (es) Queratinocitos utilizables como sustancia biologicamente activa en el tratamiento de heridas.
DE60328816D1 (de) Prozess zur verminderung des acrylamidgehaltes von hitzebehandelten lebensmitteln
DE50214734D1 (de) Oligo- oder polyalkylenglycolgekoppelte thrombininhibitoren
ATE330017T1 (de) Kallikrein gen
DE60130008D1 (de) Proteinkombinationen zur heilung von wunden
CY1112875T1 (el) Sfrp και πεπτιδικα μοτιβα που διαντιδρουν με την sfrp και μεθοδοι χρησης τους
HUP0400458A2 (hu) Kobalaminkötő fehérjéket expresszáló transzgenikus növények
BR0209541A (pt) Uso das imidazotriazinonas 2-fenil-substituìdas
ATE345354T1 (de) Methode zur identifizierung von helicobacter antigenen
IL176327A0 (en) Cc-chemokine binding proteins, their preparation and their use
TR200402030T4 (tr) İkame edilen I-aminobutan-3-ol-türevleri
WO2006076014A3 (en) Interferon-alpha constructs for use in the treatment of sars
NO20051301L (no) Proteintyrosinforfataseinhibitorer
DE60336746D1 (de) Trimer-proteine zur trimer-zytokine
DK1423429T3 (da) Antistoffer mod caspase-8 og deres fremstilling og anvendelse
DE60224026D1 (de) Rechen
ATE319744T1 (de) Antikörper zur stimulierung der produktion von il-1ra
DE60207574D1 (de) Verwendung von oxytocin zur stimulierung des pflanzenwachstums
GB0213298D0 (en) Improvements in or relating to protein production
DE60217720D1 (de) Kurkumin-zusammensetzung zur heilung von dickdarmpolypen
NO20033452D0 (no) Polynukleotid konstrukter for ökt lysin produksjon
TW200635951A (en) Specific binding agents of human angiopoietin-2

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: COBENTO A/S, DK

Free format text: FORMER OWNER(S): COBENTO BIOTECH A/S, DK

FD9A Lapse of provisional protection due to non-payment of fees